Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Van Cutsem

Showing results (71-80 of 249) with videos related to

Pageof 25
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2012
HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?D Hompes, J Tiek, A Wolthuis, et al.
Acta Gastro-Enterologica Belgica|May 10, 2012
Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of workingA Jouret-Mourin, A Hoorens, G De Hertogh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1990
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquidsJ L Urbain, G Vantrappen, J Janssens, et al.
International Journal of Colorectal Disease|January 1, 1989
Risk factors which determine the long term outcome of Neodymium-YAG laser palliation of colorectal carcinomaE Van Cutsem, A Boonen, K Geboes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)H Piessevaux, M Buyse, W De Roock, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 31, 2016
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL studyC-H Köhne, G Poston, G Folprecht, et al.
Gastroenterology|March 1, 1992
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordinationV Annese, J Janssens, G Vantrappen, et al.
British Journal of Cancer|September 19, 2013
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancerF Joulain, I Proskorovsky, C Allegra, et al.
Cancer Treatment Reviews|December 1, 2009
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patientsA G Pallis, D Papamichael, R Audisio, et al.
British Journal of Cancer|October 1, 2009
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trialA Okines, O Del Puerto, D Cunningham, et al.
Pageof 25

Showing results (71-80 of 249) with videos related to

Sort By:
Pageof 25
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2012
HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?D Hompes, J Tiek, A Wolthuis, et al.
Acta Gastro-Enterologica Belgica|May 10, 2012
Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of workingA Jouret-Mourin, A Hoorens, G De Hertogh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1990
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquidsJ L Urbain, G Vantrappen, J Janssens, et al.
International Journal of Colorectal Disease|January 1, 1989
Risk factors which determine the long term outcome of Neodymium-YAG laser palliation of colorectal carcinomaE Van Cutsem, A Boonen, K Geboes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)H Piessevaux, M Buyse, W De Roock, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 31, 2016
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL studyC-H Köhne, G Poston, G Folprecht, et al.
Gastroenterology|March 1, 1992
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordinationV Annese, J Janssens, G Vantrappen, et al.
British Journal of Cancer|September 19, 2013
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancerF Joulain, I Proskorovsky, C Allegra, et al.
Cancer Treatment Reviews|December 1, 2009
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patientsA G Pallis, D Papamichael, R Audisio, et al.
British Journal of Cancer|October 1, 2009
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trialA Okines, O Del Puerto, D Cunningham, et al.
Pageof 25